Latest Breaking News On - Algernon pharmaceuticals - Page 7 : comparemela.com

Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6 6% During the Study Period (2019–2032)

The overall market of idiopathic pulmonary fibrosis is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging therapy for idiopathic pulmonary fibrosis treatment, will boost the idiopathic pulmonary fibrosis market in the forecasted period (2023–2032).New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) |

United kingdomUnited statesNew yorkBristol myers squibbMark biosciencesVicore pharmaNitto denkoGuangdong raynoventAvalyn pharmaGilead sciencesBoehringer ingelheimHealthcare servicesKadmon corporation llcsAlgernon pharmaceuticalsAvalyn pharmaceuticalsNitto denko corporation

Chronic Kidney Disease Clinical Trial Pipeline Insights | 76+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |

Chronic Kidney Disease Clinical Trial Pipeline Insights | 76+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomEli lillySenda biosciencesScohia pharmaCaladrius biosciencesNovo nordiskBoehringer ingelheim eli lillySandeep joshiUnicocell biomedCincor pharmaKibow pharmaXenetic biosciencesRege nephroCincor pharma incKey chronic kidney disease companies

Algernon Pharmaceuticals Announces Grant of U S Patent for Repirinast in NAFLD and NASH

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFUR.

United statesUnited kingdomBritish columbiaChristopherj moreauAlgernon pharmaceuticalsCanadian securities exchangeTrademark officeAlgernon pharmaceuticals incNeither the canadian securities exchangeCompany or algernonUnited states patentTreating non alcoholic steatohepatitisMitsubishi tanabe pharmaZhejiang ausun pharmaceuticalAlgernon neuroscienceMarket regulator

Algernon Pharmaceuticals : Presentation Q3 2023 -Today at 04:49 pm

Algernon Pharmaceuticals : Presentation Q3 2023 -Today at 04:49 pm
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAlgernon pharmaceuticals incWhile the companyExchange commissionAlgernon pharmaceuticalsUnited states securities

Short Interest in Algernon Pharmaceuticals Inc (OTCMKTS:AGNPF) Grows By 33 3%

Short Interest in Algernon Pharmaceuticals Inc (OTCMKTS:AGNPF) Grows By 33 3%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New zealandAlgernon pharmaceuticalsAlgernon pharmaceuticals company profileAlgernon pharmaceuticals incAlgernon pharmaceuticals stock performanceNews ratings for algernon pharmaceuticals dailyGet free reportPharmaceuticals incAlgernon pharmaceuticals daily